Chronic intestinal pseudo-obstruction as the same symptom of various basis - review of literature
DOI:
https://doi.org/10.12775/JEHS.2024.76.56472Keywords
chronic intestinal pseudo-obstruction, cipo, gastrointestinal motility disordersAbstract
The aim of this work is to discuss the known causes of chronic intestinal pseudo-obstruction. Determining the etiology of the symptoms reported by the patient, such as: abdominal pain, bloating, nausea, constipation, heartburn or regurgitation, the cause of which cannot be clearly identified in imaging tests as mechanical intestinal obstruction, is necessary to implement proper therapy. We distinguished, among others: infections, gene mutations, cancer and paraneoplastic syndromes and autoimmune diseases. This broad range of causes shows the complexity of this disease.
Among pathogens, the most common cause are viruses, especially herpesviruses, what is more bacterial infections and gut dysbiosis must be taken under consideration. We found that specific pathway gene mutations can cause obturation symptoms which need extended diagnostic tests. Paraneoplastic syndromes should be examined as a possible etiological factor while looking for the cause of this disease and anticancer treatment can be either a solution for the chronic intestinal pseudo-obstruction symptoms or a cause of them. Lastly we discussed autoimmune diseases as a part of the inflammation problem of the bowel.
The goal is to emphasize how important it is to draw attention to the need of looking at the patient and his ailments integrally, which will enable an accurate diagnosis to be made and the appropriate treatment to be effectively selected. We found it very important to think unconventionally with every patient we deal with and what can be done thanks to a great amount of knowledge provided by other doctors.
References
Zenzeri L, Tambucci R, Quitadamo P, et al. Update on chronic intestinal pseudo-obstruction. Curr Opin Gastroenterol. 2020; 36(3): 230-237.
Radocchia G, Neroni B, Marazzato M, et al. Chronic intestinal pseudo-obstruction: is there a connection with gut microbiota? Microorganisms 2021; 9(12): 2549.
Besaw RJ, Smith MP, Zerillo JA, et al. Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab. BMJ Case Rep. 2019; 12(12): e232388.
Tanaka K, Ohkubo H, Yamamoto A, et al. Natural history of chronic intestinal pseudo-obstruction and need for palliative care. J Neurogastroenterol Motil. 2023; 29(3): 378-387.
Izumi Y, Masuda T, Horimasu Y, et al. Chronic intestinal pseudo-obstruction and orthostatic hypotension associated with small cell lung cancer that improved with tumor reduction after chemoradiotherapy. Intern Med. 2017; 56(19): 2627-2631.
Krasselt M, Exner M, Lübbert C. Ogilvie syndrome in disseminated tuberculosis. Dtsch Arztebl Int. 2019; 116(9): 145.
Herdes RE, Cagil Y, Namjoshi S, et al. Initial presentation of a pediatric intestinal pseudo-obstruction episode after SARS-CoV-2 Virus (COVID-19) Infection. JPGN Rep. 2021; 2(2): e059.
Sonsino E, Mouy R, Foucaud P, et al. Intestinal pseudoobstruction related to cytomegalovirus infection of myenteric plexus. N Engl J Med. 1984; 311(3): 196-197.
Puig I, Champeval D, De Santa Barbara P, et al. Deletion of Pten in the mouse enteric nervous system induces ganglioneuromatosis and mimics intestinal pseudoobstruction. J Clin Invest. 2009; 119(12): 3586-3596.
Antonucci A, Fronzoni L, Cogliandro L, et al. Chronic intestinal pseudo-obstruction. World J Gastroenterol. 2008; 14(19): 2953-61.
Joshua Lederberg. Infectious History. Science 2000; 288: 287-293.
Ategbo S, Turck D, Gottrand F, et al. Chronic intestinal pseudo-obstruction associated with cytomegalovirus infection in an infant. Journal of Pediatric Gastroenterology & Nutrition 1996; 23(4): 457-460.
Debinski HS, Kamm MA, Talbot IC, et al. DNA viruses in the pathogenesis of sporadic chronic idiopathic intestinal pseudo-obstruction. Gut. 1997; 41(1): 100-106.
Greenberg J, Greenberg J, Helmstetter N. Chronic intestinal pseudo-obstruction due to Strongyloides stercoralis. IDCases 2018; 13: e00425.
Pessarelli T, Basilisco G, Spina L, et al. Intestinal pseudo-obstruction caused by Giardia lamblia infection. BMJ Case Rep. 2022; 15(11): e252319.
Sinagra E, Pellegatta G, Maida M, et al. Could chronic idiopatic intestinal pseudo-obstruction be related to viral infections? J Clin Med. 2021; 10(2): 268.
Carod-Artal FJ. The enteric nervous system: another forgotten autonomic target in viral infections? Clin Auton Res. 2017; 27(3): 137-138.
Lee SW, Ko CW, Liao SC, et al. A case with vitamin D deficiency-induced cytomegalovirus enteritis presenting as bowel pseudo-obstruction. Gastroenterology Res. 2017; 10(3): 193-195.
Besnard M, Faure C, Fromont-Hankard G, et al. Intestinal pseudo-obstruction and acute pandysautonomia associated with Epstein-Barr virus infection. Am J Gastroenterol. 2000; 95(1): 280-284.
Pinto M, Dobson S. BK and JC virus: a review. J Infect. 2014; 68(1): 2-8.
Selgrad M, De Giorgio R, Fini L, et al. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. Gut. 2009; 58(1): 25-32.
Sinagra E, Raimondo D, Gallo E, et al. Could JC virus be linked to chronic idiopathic intestinal pseudo-obstruction? Clin J Gastroenterol. 2020; 13(3): 377-381.
Chatila R, Kapadia CR. Intestinal pseudoobstruction in acute Lyme disease: a case report. Am J Gastroenterol. 1998; 93(7): 1179-1180.
Gu L, Ding C, Tian H, et al. Serial frozen fecal microbiota transplantation in the treatment of chronic intestinal pseudo-obstruction: a preliminary study. J Neurogastroenterol Motil. 2017; 23(2): 289-297.
Le TL, Galmiche L, Levy J, et al. Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans. J Clin Invest. 2021; 131(6): e145837.
Bianco F, Lattanzio G, Lorenzini L, et al. Enteric neuromyopathies: highlights on genetic mechanisms underlying chronic intestinal pseudo-obstruction. Biomolecules 2022; 12(12): 1849.
Skelton PD, Stan RV, Luikart BW. The role of PTEN in neurodevelopment. Mol Neuropsychiatry 2020; 5(1): 60-71.
Panigrahi AR, Pinder SE, Chan SY, et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. The Journal of Pathology 2004; 204(1); 93-100.
Hirano M, Carelli V, De Giorgio R, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): position paper on diagnosis, prognosis, and treatment by the MNGIE International Network. J Inherit Metab Dis. 2021; 44(2): 376-387.
Hirano M, Nishigaki Y, Martí R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist. 2004;10(1): 8-17.
Granero Castro P, Fernández Arias S, Moreno Gijón M, et al. Emergency surgery in chronic intestinal pseudo-obstruction due to mitochondrial neurogastrointestinal encephalomyopathy: case reports. Int Arch Med. 2010; 3: 35.
Hirano M, Martí R, Casali C, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology. 2006; 67(8): 1458-1460.
Fournier N, Fabre A. Smooth muscle motility disorder phenotypes: A systematic review of cases associated with seven pathogenic genes (ACTG2, MYH11, FLNA, MYLK, RAD21, MYL9 and LMOD1). Intractable Rare Dis Res. 2022; 11(3): 113-119.
Rana JS, Khan SS, Lloyd-Jones DM, et al. Changes in mortality in top 10 causes of death from 2011 to 2018. J Gen Intern Med. 2021; 36(8): 2517-2518.
Koo MM, Swann R, McPhail S, et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 2020; 21(1): 73-79.
Thapa B, Mahendraker N, Ramphul K. Paraneoplastic Syndromes. 2023 Mar 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Sardiña González C, Martínez Vivero C, López Castro J. Paraneoplastic syndromes review: The great forgotten ones. Crit Rev Oncol Hematol. 2022; 174: 103676.
Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010; 85(9): 838-854.
Taverna JA, Babiker HM, Yun S, et al. The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res. 2014; 2(1): 23.
Amiot A, Joly F, Messing B, et al. Pseudo-obstruction intestinale chronique et syndrome des anti-Hu : 13 ans de suivi sans apparition de néoplasie. Gastroentérologie Clinique et Biologique 2008; 32(1): 51-55.
Lee HR, Lennon VA, Camilleri M, et al. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol. 2001; 96(2): 373-379.
Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017; 8:730.
Besaw RJ, Smith MP, Zerillo JA, et al. Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab. BMJ Case Rep. 2019; 12(12): e232388.
Perlemuter G, Chaussade S, Wechsler B, et al. Chronic intestinal pseudo-obstruction in systemic lupus erythematosus. Gut 1998; 43: 117-122.
Mok MY, Wong RW, Lau CS. Intestinal pseudo-obstruction in systemic lupus erythematosus: an uncommon but important clinical manifestation. Lupus 2000; 9: 11-18.
Hill PA, Dwyer KM, Power DA. Chronic intestinal pseudoobstruction in systemic lupus erythematosus due to intestinal smooth muscle myopathy. Lupus 2000; 9: 458-463.
Pardos-Gea J, Ordi-Ros J, Selva A, et al. Chronic intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus. Lupus 2005; 14: 328-330.
Park FD, Lee JK, Madduri GD, et al. Generalized megaviscera of lupus: refractory intestinal pseudo-obstruction, ureterohydronephrosis and megacholedochus. World J Gastroenterol. 2009; 15(28): 3555-3559.
Nojima Y, Mimura T, Hamasaki K, et al. Chronic intestinal pseudoobstruction associated with autoantibodies against proliferating cell nuclear antigen. Arthritis Rheum 1996; 39: 877-879.
Turner R, Lipshutz W, Miller W, et al. Esophageal dysfunction in collagen disease. Am J Med Sci. 1973; 265(3): 191–199.
Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989; 28(4): 281–286.
Gyger G, Baron M. Systemic Sclerosis: Gastrointestinal disease and its management. Rheum Dis Clin North Am. 2015; 41(3): 459–473.
Shah J, Shahidullah A. Chronic intestinal pseudo-obstruction in systemic sclerosis: an uncommon presentation. Case Rep Gastroenterol. 2018; 12(2): 373-378.
Black CM. The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994. J R Coll Physicians Lond. 1995; 29(2): 119-130.
Denton CP, Black CM, Korn JH, et al. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996; 347(9013): 1453–1458.
Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996; 8(6): 569–575.
Valenzuela A, Li S, Becker L, et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology 2016; 55(4): 654–658.
Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991; 325(21): 1461–1467.
Zhu CZ, Zhao HW, Lin HW, et al. Latest developments in chronic intestinal pseudo-obstruction. World J Clin Cases. 2020; 8(23): 5852-5865.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Grzegorczyk, Magdalena Pachla, Nicol Dardzińska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 69
Number of citations: 0